ADHD medications and risk of serious cardiovascular events in young and middle-aged adults

JAMA

Volumn 306, Issue 24, 2011, Pages 2673-2683

  Habel, Laurel A ^a   Cooper, William O ^b,c   Sox, Colin M ^d,e   Chan, K Arnold ^f   Fireman, Bruce H ^a   Arbogast, Patrick G ^b   Cheetham, T Craig ^g   Quinn, Virginia P ^g   Dublin, Sascha ^h,i   Boudreau, Denise M ^h,i   Andrade, Susan E ^j   Pawloski, Pamala A ^k   Raebel, Marsha A ^g,l   Smith, David H ^m   Achacoso, Ninah ^a   Uratsu, Connie ^a   Go, Alan S ^a   Sidney, Steve ^a,n   Nguyen Huynh, Mai N ^a   Ray, Wayne A ^c   Selby, Joe V ^a   more..

^a DIVISION OF RESEARCH   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f OPTUM   (United States)

^g KAISER PERMANENTE   (United States)

^h GROUP HEALTH RESEARCH INSTITUTE   (United States)

ⁱ UNIVERSITY OF WASHINGTON   (United States)

^j UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^k HEALTHPARTNERS RESEARCH FOUNDATION   (United States)

^l UNIVERSITY OF COLORADO   (United States)

^m CENTER FOR HEALTH RESEARCH   (United States)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; AMPHETAMINE DERIVATIVE; ATOMOXETINE; DEXAMPHETAMINE; METHYLPHENIDATE; PEMOLINE;

ADULT; AGED; ARTICLE; ATTENTION DEFICIT DISORDER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG SAFETY; DRUG USE; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; PROTECTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; STROKE; SUDDEN DEATH; TREATMENT DURATION; UNITED STATES;

EID: 84555187324     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.1830     Document Type: Article

References (36)

1. New Report: America's State of Mind. Medco Web site. http://medco. mediaroom.com/. 2011. Accessed November 16, 2011.
2. Food and Drug Administration. Drug Safety and Risk Management Advisory Committee meeting. http://www.fda.gov/ohrms/dockets/ac/cder06 .html#DrugSafetyRiskMgmt. Food and Drug Administration Web site. February 9-10, 2006. Accessed November 21, 2011.
3. Montejano L, Sasané R, Hodgkins P, Russo L, Huse D. Adult ADHD: prevalence of diagnosis in a US population with employer health insurance. Curr Med Res Opin. 2011;27(suppl 2):5-11.
4. Wilens TE, Morrison NR, Prince J. An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adults. Expert Rev Neurother. 2011;11(10): 1443-1465.
5. Challman TD, Lipsky JJ. Methylphenidate: its pharmacology and uses. Mayo Clin Proc. 2000;75(7): 711-721. (Pubitemid 30441501)
6. Leddy JJ, Epstein LH, Jaroni JL, et al. Influence of methylphenidate on eating in obese men. Obes Res. 2004; 12(2):224-232. (Pubitemid 41132545)
7. Frierson RL, Wey JJ, Tabler JB. Psychostimulants for depression in the medically ill. Am Fam Physician. 1991; 43(1):163-170.
8. Tharwani HM, Yerramsetty P, Mannelli P, Patkar A, Masand P. Recent advances in poststroke depression. Curr Psychiatry Rep. 2007;9(3):225-231. (Pubitemid 46895100)
9. Warden DL, Gordon B, McAllister TW, et al. Neurobehavioral Guidelines Working Group. Guidelines for the pharmacologic treatment of neurobehavioral sequelae of traumatic brain injury. J Neurotrauma. 2006; 23(10):1468-1501. (Pubitemid 46489606)
10. Hammerness PG, Surman CB, Chilton A. Adult attention- deficit/hyperactivity disorder treatment and cardiovascular implications. Curr Psychiatry Rep. 2011; 13(5):357-363.
11. Stiefel G, Besag FM. Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder. Drug Saf. 2010;33(10):821-842.
12. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349): 1903-1913. (Pubitemid 35472129)
13. Gould MS, Walsh BT, Munfakh JL, et al. Sudden death and use of stimulant medications in youths. Am J Psychiatry. 2009;166(9):992-1001.
14. Winterstein AG, Gerhard T, Shuster J, Johnson M, Zito JM, Saidi A. Cardiac safety of central nervous system stimulants in children and adolescents with attentiondeficit/ hyperactivity disorder. Pediatrics. 2007;120 (6):e1494-e1501.
15. Schelleman H, Bilker WB, Strom BL, et al. Cardiovascular events and death in children exposed and unexposed to ADHD agents. Pediatrics. 2011;127 (6):1102-1110.
16. Winterstein AG, Gerhard T, Shuster J, Saidi A. Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD. Pediatrics. 2009;124 (1):e75-e80.
17. Holick CN, Turnbull BR, Jones ME, Chaudhry S, Bangs ME, Seeger JD. Atomoxetine and cerebrovascular outcomes in adults. J Clin Psychopharmacol. 2009; 29(5):453-460.
18. McCarthy S, Cranswick N, Potts L, Taylor E,Wong IC.Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database. Drug Saf. 2009;32(11):1089-1096.
19. Cooper WO,Habel LA, Sox CM, et al.ADHDdrugs and serious cardiovascular events in children and young adults. N Engl J Med. 2011;365(20):1896- 1904.
20. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000;36 (3):959-969.
21. Meier MA, Al-Badr WH, Cooper JV, et al. The new definition ofmyocardial infarction: diagnostic and prognostic implications in patients with acute coronary syndromes. Arch Intern Med. 2002;162(14):1585- 1589.
22. Chung CP, Murray KT, Stein CM, Hall K, Ray WA. A computer case definition for sudden cardiac death. Pharmacoepidemiol Drug Saf. 2010;19(6):563-572.
23. Miettinen OS. Stratification by a multivariate confounder score. Am J Epidemiol. 1976;104(6):609- 620.
24. Arbogast PG, Ray WA. Use of disease risk scores in pharmacoepidemiologic studies. Stat Methods Med Res. 2009;18(1):67-80.
25. Glynn RJ, Schneeweiss S, Stürmer T. Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol. 2006;98(3):253-259.
26. Suissa S, Edwardes MD. Adjusted odds ratios for case-control studies with missing confounder data in controls. Epidemiology. 1997;8(3):275-280. (Pubitemid 27183692)
27. Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf. 2006;15(5):291-303. (Pubitemid 43797117)
28. Schneeweiss S, Glynn RJ, Tsai EH, Avorn J, Solomon DH. Adjusting for unmeasured confounders in pharmacoepidemiologic claims data using external information: the example of COX2 inhibitors and myocardial infarction. Epidemiology. 2005;16(1):17-24. (Pubitemid 40239274)
29. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003; 158(9):915-920. (Pubitemid 37323253)
30. West SL, Strom BL, Polle C. Validity of pharmacoepidemiologic drug and diagnosis data. In: Strom BL, ed. Pharmacoepidemiology. Philadelphia, PA: John Wiley & Sons Ltd; 2005:709-765.
31. de Burgos-Lunar C, Salinero-Fort MA, Cárdenas-Valladolid J, et al. Validation of diabetes mellitus and hypertension diagnosis in computerized medical records in primary health care. BMC Med Res Methodol. 2011;11:146.
32. Thygesen SK, Christiansen CF, Christensen S, Lash TL, Sørensen HT. The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients. BMC Med Res Methodol. 2011;11:83.
33. Grijalva CG, Chung CP, Stein CM, et al. Computerized definitions showed high positive predictive values for identifying hospitalizations for congestive heart failure and selected infections in Medicaid enrollees with rheumatoid arthritis. Pharmacoepidemiol Drug Saf. 2008; 17(9):890-895.
34. Adler LA, Zimmerman B, Starr HL, et al. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, doseescalation study. J Clin Psychopharmacol. 2009; 29(3):239-247.
35. Peterson K, McDonagh MS, Fu R. Comparative benefits and harms of competing medications for adults with attention-deficit hyperactivity disorder: a systematic review and indirect comparison meta-analysis. Psychopharmacology (Berl). 2008;197(1):1-11.
36. Cohen AL, Jhung MA, Budnitz DS. Stimulant medications and attention deficit-hyperactivity disorder. N Engl J Med. 2006;354(21):2294-2295. (Pubitemid 43788161)